Suppression of Immunotherapy on Group 2 Innate Lymphoid Cells in Allergic Rhinitis.
Suppression of Immunotherapy on Group 2 Innate Lymphoid Cells in Allergic Rhinitis.
复制标题
过敏性鼻炎第 2 组先天淋巴细胞免疫治疗的抑制
DOI：
10.4103/0366-6999.194642
复制
发表时间：
2016-12-05
影响因子：
6.1
通讯作者：
Zhang L
中科院分区：
文献类型：
--
作者：
Fan DC;Wang XD;Wang CS;Wang Y;Cao FF;Zhang L
背景：第2组先天性淋巴样细胞（ILC 2）被认为是一种新的谱系阴性细胞群体，其通过产生关键的Th 2型细胞因子白细胞介素（IL）-5和IL-13来诱导先天性2型应答。ILC 2在变应性鼻炎（AR）的发病中起重要作用，但屋尘螨提取物（Der p-SCIT）皮下免疫治疗（SCIT）对AR患者ILC 2的影响尚不清楚。本研究旨在探讨屋尘螨致敏的中国AR患者接受Der P提取物SCIT后外周血ILC 2的反应。方法：7名没有AR症状的健康对照者，他们对皮肤点刺试验中的任何过敏原均呈阴性反应，9名根据过敏性鼻炎及其对哮喘的影响（ARIA）指南诊断为持续性AR的患者，以及24名接受Der p-SCIT治疗的AR患者。研究招募了1.0-3.5年。使用流式细胞术评估外周血中的ILC 2。所有参与者的症状的严重程度根据总5症状评分进行评级。结果：在40名参与者中，9名AR患者被分配到未治疗组，24名接受Der p-SCIT的AR患者被分配到免疫治疗组，7名无AR症状的健康对照被分配到健康对照组。免疫治疗组5项症状总评分（4.3 ± 1.4）分明显低于未治疗组（10.1 ± 2.5）分（P < 0.001）。免疫治疗组外周血ILC 2s水平较未治疗组显著降低（P < 0.001），但与健康对照组比较差异无统计学意义（P = 0.775）。基于SCIT治疗持续时间的进一步亚组分析（1.0-2.0年[SCIT 1 -2]、2.0-3.0年[SCIT 2 -3]和3.0-3.5年[SCIT 3 -3.5]）显示，SCIT 1 -2、SCIT 2 -3和SCIT 3 -3.5组之间ILC 2的百分比无显著差异（SCIT 1 -2 vs. SCIT 2 -3：P = 0.268; SCIT 1 -2 vs. SCIT 3 -3.5：P = 0.635; SCIT 2 -3 vs. SCIT 3 -3.5：P = 0.787）。结论：本研究强调了Der p-SCIT对HDM-AR患者ILC 2的抑制。在外周血中鉴定的ILC 2可用作Der p-SCIT的有效生物标志物。
Background:Group 2 innate lymphoid cells (ILC2s) are regarded as a novel population of lineage-negative cells that induce innate Type 2 responses by producing the critical Th2-type cytokines interleukin (IL)-5 and IL-13. ILC2s as key players in the development of allergic rhinitis (AR) have been proved, however, the effect of subcutaneous immunotherapy (SCIT) with dermatophagoides pteronyssinus extract (Der p-SCIT) on ILC2s in AR patients is not clear. This study aimed to investigate the response of ILC2s of peripheral blood in house dust mites (HDM)-sensitized Chinese patients with AR who received SCIT with Der P extract. Methods:Seven healthy controls without symptoms of AR who had negative reactions to any of the allergens from skin-prick testing, nine patients diagnosed with persistent AR according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, and 24 AR patients who received Der p-SCIT for 1.0–3.5 years were recruited for the study. ILC2s in the peripheral blood were evaluated using flow cytometry. The severity of their symptoms of all participants was rated based on the Total 5 symptom score. Results:Among 40 participants, 9 AR patients were assigned to the untreated group, 24 AR patients receiving Der p-SCIT were assigned to the immunotherapy group, and 7 healthy controls without symptoms of AR were assigned to healthy control group. The mean Total 5 symptom score of immunotherapy group was significantly lower than that of untreated group (4.3 ± 1.4 vs. 10.1 ± 2.5, P < 0.001). Similarly, the levels of ILC2s in the peripheral blood of immunotherapy group were significantly reduced compared with that in untreated group (P < 0.001), but were not significantly different from healthy controls (P = 0.775). Further subgroup analysis based on the duration of SCIT therapy (1.0–2.0 years [SCIT1-2], 2.0–3.0 years [SCIT2-3], and 3.0–3.5 years [SCIT3-3.5]) showed that the percentage of ILC2s was not significantly different between SCIT1-2, SCIT2-3, and SCIT3-3.5 groups (SCIT1-2 vs. SCIT2-3: P = 0.268; SCIT1-2 vs. SCIT3-3.5: P = 0.635; and SCIT2-3 vs. SCIT3-3.5: P = 0.787). Conclusions:The present study highlighted the suppression of Der p-SCIT on ILC2s in HDM-AR patients. ILC2s identified in peripheral blood can be used as an effective biomarker for Der p-SCIT.
登录
查看更多内容
影响因子：
4.4
作者：
Lou, Wei;Wang, Chengshuo;Zhang, Luo
通讯作者：
Zhang, Luo
影响因子：
20.3
作者：
Banh, Cindy;Fugere, Celine;Brossay, Laurent
通讯作者：
Brossay, Laurent
影响因子：
2.8
作者：
Kobayashi, N;Dezawa, M;Konno, A
通讯作者：
Konno, A
DOI：
10.1073/pnas.1003988107
发表时间：
2010-06-22
影响因子：
11.1
作者：
Price, April E.;Liang, Hong-Erh;Locksley, Richard M.
通讯作者：
Locksley, Richard M.
影响因子：
12.4
作者：
Li, J.;Sun, B.;Zhong, N.
通讯作者：
Zhong, N.